Randomised, double-blind, placebo-controlled clinical trial investigating the effects of inorganic nitrate in hypertension-induced target organ damage: protocol of the NITRATE-TOD study in the UK by Lau, CWZ et al.
1Lau CWZ, et al. BMJ Open 2020;10:e034399. doi:10.1136/bmjopen-2019-034399
Open access 
Randomised, double- blind, placebo- 
controlled clinical trial investigating the 
effects of inorganic nitrate in 
hypertension- induced target organ 
damage: protocol of the NITRATE- TOD 
study in the UK
Clement Wai Zhen Lau   ,1,2 Alexander Jozua Pedro Hamers,1 
Krishnaraj Sinhji Rathod,1,2 Asad Shabbir,1 Jackie Cooper,1 
Christopher Peter Primus,1,2 Ceri Davies,1,2 Anthony Mathur,1,2 James C Moon,2,3 
Vikas Kapil,1,2 Amrita Ahluwalia1
To cite: Lau CWZ, Hamers AJP, 
Rathod KS, et al.  Randomised, 
double- blind, placebo- controlled 
clinical trial investigating the 
effects of inorganic nitrate 
in hypertension- induced 
target organ damage: 
protocol of the NITRATE- TOD 
study in the UK. BMJ Open 
2020;10:e034399. doi:10.1136/
bmjopen-2019-034399
 ► Prepublication history for 
this paper is available online. 
To view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2019- 
034399).
Received 19 September 2019
Revised 20 November 2019
Accepted 22 November 2019
For numbered affiliations see 
end of article.
Correspondence to
Professor Amrita Ahluwalia;  
 a. ahluwalia@ qmul. ac. uk
Protocol
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
AbstrACt
Introduction Arterial stiffness and left ventricular 
(LV) hypertrophy are the key markers of hypertensive 
target organ damage (TOD) associated with increased 
cardiovascular morbidity and mortality. We have previously 
shown that dietary inorganic nitrate supplementation 
lowers blood pressure (BP) in hypertension, however, 
whether this approach might also improve markers 
of hypertensive TOD is unknown. In this study, we 
will investigate whether daily dietary inorganic nitrate 
administration reduces LV mass and improves measures of 
arterial stiffness.
Methods and design NITRATE- TOD is a double- blind, 
randomised, single- centre, placebo- controlled phase 
II trial aiming to enrol 160 patients with suboptimal BP 
control on one or more antihypertensives. Patients will be 
randomised to receive 4 months once daily dose of either 
nitrate- rich beetroot juice or nitrate- deplete beetroot 
juice (placebo). The primary outcomes are reduction in 
LV mass and reduction in pulse wave velocity (PWV) and 
central BP.
The study has a power of 95% for detecting a 9 g LV mass 
change by cardiovascular MRI (~6% change for a mildly 
hypertrophied heart of 150 g). For PWV, we have a power of 
>95% for detecting a 0.6 m/s absolute change. For central 
systolic BP, we have a>90% power to detect a 5.8 mm Hg 
difference in central systolic BP.
Secondary end points include change in ultrasound flow- 
mediated dilation, change in plasma nitrate and nitrite 
concentration and change in BP.
Ethics and dissemination The study was approved by 
the London—City and East Research Ethics Committee 
(10/H0703/98). Trial results will be published according to 
the Consolidated Standards of Reporting Trials statement 
and will be presented at conferences and reported in peer- 
reviewed journals.
trial registration number NCT03088514
IntroduCtIon
Hypertension is the leading risk factor 
for cardiovascular diseases (CVDs) world-
wide.1 2 In 2016, an estimated 17.9 million 
people died from CVDs, which represents 
31% of all global deaths.3 Approximately half 
of these deaths were caused by complications 
from hypertension.4 Hence, novel and cost- 
effective therapeutic strategies continue to 
be sought. In this regard, there has been a 
major emphasis to increase vegetable intake 
since increased consumption of a vegetable- 
rich diet particularly green leafy vegetables 
confers protection against CVD, including 
the lowering of blood pressure (BP).5 6 One 
particular constituent of such vegetables that 
has been proposed to underlie the beneficial 
effects of this food group is inorganic nitrate; 
through bioconversion to nitrite, and then 
nitrite to nitric oxide (NO)7 in the body. 
Importantly, provision of inorganic nitrate to 
strengths and limitations of this study
 ► This is a randomised, placebo- controlled double- 
blind clinical trial assessing the potential of dietary 
nitrate in reducing both cardiac and vascular dam-
age due to persistently elevated blood pressure.
 ► Dietary nitrate is a simple, easy to use and safe in-
tervention that may be more acceptable to patients 
on long- term medication for their blood pressure.
 ► This is a single- centre phase II study; therefore, the 
applicability to other centres is uncertain.
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hypertensive patients causes a rise in plasma nitrate and is 
associated with a decrease in BP.8 9
Dietary inorganic nitrate once ingested rapidly enters 
the circulation8–10 with a proportion of this nitrate being 
extracted and then secreted and concentrated in the 
saliva.11 Bacteria residing in the oral cavity convert this 
nitrate to nitrite which is then swallowed12; appearing 
soon after within the circulation. We have recently 
shown that daily supplementation with dietary nitrate 
(providing approximately 6.4 mmol nitrate daily) for 4 
weeks was associated with robust, sustained and clinically 
meaningful reductions in BP (measured by clinic, ambu-
latory and home methods) of ~8/4 mm Hg.13 However, 
persistent hypertension leads to both vascular and cardiac 
remodelling and whether inorganic nitrate- induced 
reductions in BP might be associated with improvements 
in either of these in the long term is unknown. Experi-
mentally in patients one can assess this potential through 
the measurement of arterial stiffness and left ventricular 
(LV) mass, respectively, with increases of either confer-
ring increased CV risk. Arterial stiffness (and its inverse 
measure, distensibility) refers to the decreased elasticity 
that develops in arteries as a consequence of vascular 
remodelling resulting from alterations of the fibrous 
components of the extracellular matrix (including elastin 
and collagen).14 Importantly, increased arterial stiffness, 
as measured using carotid- femoral pulse wave velocity 
(PWV),15 is a strong predictor of CV events,16 and there 
have been suggestions that drug development targeting 
this phenomenon is likely to provide a new genre of ther-
apeutics in the combat against CVD.17 Additionally, an 
increased central pulse pressure occurs when the large 
conduit blood vessels lose their elasticity and become less 
able to accommodate all of the blood ejected from the 
heart. This increase in pressure results in an increase in 
central systolic BP and causes an increase in the stress 
imposed on the left ventricle, which in turn can result in 
LV hypertrophy (LVH).18 Elevated LV mass is an initial 
compensatory mechanism to normalise wall stress due to 
elevated BP. However, this cardiac remodelling eventu-
ally becomes maladaptive with an increase in myocardial 
oxygen consumption, cardiac chamber dilation, reduced 
LV contractility and progressive deterioration to heart 
failure.19 The measure of LVH as a prognostic indicator 
of adverse outcome was first convincingly identified in the 
Framingham study,20 and numerous studies since have 
confirmed the strong relationship between LVH and CV 
events and mortality.21 22 Perhaps, more importantly, LV 
mass reduction is associated with further improvements 
in CV outcomes.23 24
It has been proposed that insufficient supply of endog-
enous NO likely contributes to the progression and wors-
ening of arterial stiffness and LVH.25 Preclinical studies 
have demonstrated that an elevation of systemic nitrite 
levels reduces cardiac hypertrophy in mice.26 More-
over, administration of inorganic nitrate reduces PWV 
healthy volunteers and hypertensive patients in short- 
term studies.13 27 It is also possible that decreasing arterial 
stiffness improves ventricular–arterial coupling which 
might result in benefits in cardiac function.28
The objective of this study is to determine whether a 
dietary nitrate intervention might elevate the levels of 
NO in the body sufficiently to alter both heart and blood 
vessel remodelling in hypertensive patients with subop-
timal BP control.
MEthodology
trial objectives
Aims of research
We wish to test the hypothesis that dietary supplemen-
tation of inorganic nitrate (in beetroot juice) elevates 
circulating nitrate and nitrite levels ultimately delivering 
NO to the vasculature and thereby improving endothe-
lial, vascular and cardiac function in patients with treated 
yet uncontrolled hypertension. Specifically, the aim is to 
investigate whether prolonged dietary nitrate ingestion 
in hypertensive patients with suboptimal BP control, can 
cause reductions in LV mass and PWV.
Participant selection
This is a single- centre study, in which patients will be 
identified and recruited at Barts Health National Health 
Service (NHS) Trust. In addition, other participant iden-
tification centres will be used to identify suitable partic-
ipants via the National Institute for Health Research 
(NIHR) Clinical Research Network and local NHS Trusts.
original hypothesis
Dietary inorganic nitrate ingestion, in addition to existing 
pharmacological therapy, reduces BP leading to reduc-
tions in LV mass and arterial stiffness.
Primary end points
The primary end points are change in LV mass, deter-
mined using cardiovascular MRI (CMR) (NITRATE- LVH 
arm) and a change in central systolic BP and PWV 
(NITRATE- CBP arm).
secondary end points
Secondary endpoints are change in ultrasound deter-
mined brachial artery flow- mediated dilation (FMD), 
change in plasma nitrate and nitrite levels and a change 
in peripheral BP.
Exploratory end points
Exploratory end points for cardiac imaging include a 
change in aortic distensibility, LV systolic and diastolic 
function, LV volumes and ejection fraction, left atrial 
volumes and function and markers of myocardial fibrosis 
and oedema. We will assess changes in 12- lead ECG 
parameters of LVH. With regard to BP, we will assess for 
changes in BP variability, BP control rate and BP circa-
dian pattern. We will also perform analysis of the salivary 
microbiome. Finally, we will assess changes in quality 
of life score (EQ- 5D questionnaire) and biochemical 
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measures for example, urine albumin excretion, choles-
terol fractions, B- natriuretic peptide and troponin T.
InClusIon CrItErIA
A subject will be eligible for inclusion in this study only if 
all of the following criteria apply:
1. Patients will be enrolled following an informed 
consent.
2. Aged 18–80 years.
3. The study subjects will be hypertensive with evidence 
of difficulty treating to target BP (daytime ambulatory 
BP monitor 135–170 and/or 85–105 mm Hg) on one 
or more antihypertensive agent, with insufficient effi-
cacy or intolerance of medications.
4. For the NITRATE- LVH arm, echocardiographic evi-
dence of LVH (LV mass indexed to body surface area 
(BSA); males >115 g/m2; females >95 g/m2).
5. Patients will have been established on an antihyper-
tensive treatment regime for at least 1 month by the 
time of participation in the study and will not require 
changes in pharmacological intervention for the dura-
tion of the trial.
ExClusIon CrItErIA
Unless specified, a subject will not be eligible for inclu-
sion in this study if any of the following criteria apply:
1. History of chronic viral hepatitis (including presence 
of hepatitis B surface antigen or hepatitis C antibody) 
or other chronic hepatic disorders.
2. History of increased liver function tests (alanine 
transaminase (ALT), aspartate transaminase (AST)) 
due to acute or chronic liver conditions, 3x above the 
upper limit of normal or bilirubin 1.5x above the up-
per limit of normal at screening.
3. Renal impairment with creatinine clearance (estimat-
ed glomerular filtration rate (eGFR)) of <50 mL/min 
at screening.
4. Patients with diabetes mellitus defined by previous 
history of diabetes or haemoglobin A1c (HbA1c) 
>6.5% (>48 mmol/mol) at screening.
5. Subjects with low- density lipoprotein cholester-
ol (LDLc), >7.5 mmol/L and/or triglyceride level 
>10 mmol/L.
6. History of heart failure defined as New York Heart 
Association (NYHA) class II–IV or those with known 
LV dysfunction (LV ejection fraction <40%) regard-
less of symptomatic status.
7. History of malignancy within the past 5 years, other 
than non- melanoma skin cancer.
8. Current life- threatening condition other than vascu-
lar disease (eg, very severe chronic airways disease, 
HIV positive, life‐threatening arrhythmias) that may 
prevent a subject from completing the study.
9. Use of an investigational device or investigational 
drug within 30 days or five half- lives (whichever is 
longer) preceding the first dose of study medication.
10. Subjects who will commence or who are likely to 
commence regular treatment with non- steroidal 
anti- inflammatory drugs (other than aspirin), from 
screening until study completion.
11. Any non- stable dosing of ongoing medication regi-
mens throughout the study trial.
12. Drug abuse within the past 6 months.
13. The subject has a 3- month prior history of regular al-
cohol consumption exceeding an average weekly in-
take of >28 units (or an average daily intake of greater 
than three units) for males, or an average weekly in-
take of >21 units (or an average daily intake of great-
er than two units) for females. 1 unit is equivalent to 
a half- pint (284 mL) of beer/lager; 25 mL measure of 
spirits or 125 mL of wine.
14. Any other subject whom the investigator deems unsuit-
able for the study (eg, due to other medical reasons, 
laboratory abnormalities, expected study medication 
non- compliance or subject’s unwillingness to comply 
with all study- related study procedures).
15. Subjects with rheumatoid arthritis, connective tissue 
disorders and other conditions known to be associ-
ated with chronic inflammation (eg, inflammatory 
bowel disease).
16. Subjects with any acute infection or recent systemic 
(oral or intravenous) antibiotics within 1 month of 
screening, or significant trauma (burns, fractures).
17. Subjects who have donated more than 500 mL of 
blood within 56 days prior to the study medication 
administration.
18. Self- reported use of antimicrobial mouthwash or 
tongue scrapes.
19. Concomitant xanthine oxidase inhibitors (such as 
allopurinol).
20. Known history of significant claustrophobia, previous 
intolerance of CMR or known (or suspected) incom-
patible metallic implant.
21. Pregnancy.
22. Allergy to gadolinium- based contrast agents used for 
CMR.
23. Patients with known LVH caused by another estab-
lished pathology diagnosed prior to or at screening, 
for example, severe aortic stenosis, hypertrophic car-
diomyopathy, amyloidosis and Fabry disease.
Exceptions to the exclusion criteria:
 ► For criteria 18, patients can enter the trial if they 
discontinue the use of antimicrobial mouthwash for 
the duration of the clinical trial.
 ► Criteria 20 and 22 do not apply to participants who 
will not have a CMR scan in the NITRATE- CBP arm.
study design and intervention
This is a prospective double- blind, placebo- controlled, 
clinical study. A total of 160 patients (male and female, 
age 18–80) with hypertension as per requirements indi-
cated above will be recruited. Figure 1 shows a summary 
of the study scheme. Patients will be stratified at screening 
into two arms. Participants with LVH at screening 
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Figure 1 Study protocol. ABPM, ambulatory blood pressure monitor; BP, blood pressure; CBP, central blood pressure; CMR, 
cardiovascular magnetic resonance; FMD, flow- mediated dilation; LVH, left ventricular hypertrophy; PWA, pulse wave analysis; 
PWV, pulse wave velocity.
echocardiography will enter the NITRATE- LVH arm 
(n=80) while those who do not have LVH but satisfy the 
other eligibility criteria will enter the NITRATE- CBP arm 
(n=80). LVH is defined by increased LV mass determined 
by acquiring a parasternal long- axis image and subse-
quently measured for the interventricular septal wall 
thickness, end- diastolic LV cavity diameter and posterior 
LV wall thickness according to published guidelines.29 LV 
mass is calculated as previously described and indexed to 
BSA.30
All visits will take place at the William Harvey Heart 
Centre, Queen Mary University of London and Barts 
Heart Centre, St Bartholomew’s Hospital, Barts Health 
NHS Trust. Patients will be randomised to receive 70 mL 
of a beetroot juice concentrate containing ∼6 mmol 
nitrate or nitrate- depleted placebo juice concentrate 
(James White Drinks, UK) control. The volunteers will 
start taking their daily dose after completion of their base-
line visit (visit 1) for 16 weeks. Patients will be advised to 
take their dose of juice at the same time each day, prefer-
ably in the morning with their breakfast. Patients will be 
provided with dietary advice in relation to the calorific 
content of interventions (both ∼100 kcal). In addition 
to baseline and 16 week visits, patients will return to the 
clinic at 8 weeks for collection of samples for NOx anal-
ysis and for discussion of any adherence issues.
randomisation and blinding process
Patients will be block randomised on a 1:1 basis to receive 
either dietary nitrate or placebo, using a binary random 
number sequence (http://www. random. org). Treatment 
assignment for volunteers in the dietary nitrate and 
placebo groups will remain blinded until data lock and 
statistical analysis at the end of the study. If unblinding 
is required, the chief investigator for the study will be 
informed. A list of the unblinded treatments will be kept 
in a secure location at the Barts Cardiovascular Clinical 
Trials Unit (CVCTU). The unblinding procedure will be 
available at all times.
Patient and public involvement
Patients were directly involved in the design and planning 
of the study. Twenty previous Barts Health NHS Trust 
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patients were surveyed regarding aspects of trials involving 
dietary interventions, which informed this protocol.
study start and end dates
Recruitment commenced on 23 March 2017. The provi-
sional end date for recruitment is September 2020.
Methods to be used
Blood, saliva and urine analysis
In this study, venous blood will be taken using a 21- gauge 
butterfly needle at each visit. Blood samples will be centri-
fuged immediately and plasma separated. The plasma 
samples will be snap frozen in liquid nitrogen and stored 
at −80°C. These samples will be used for the purposes of 
making biochemical measurements and will be discarded 
once used. Similarly, saliva and urine will be collected at 
each visit. Saliva will be centrifuged, and a pellet gener-
ated. This pellet contains oral bacteria that have dislodged 
from the oral cavity. This pellet will be frozen for later 
analysis of oral bacteria by second- generation genome 
sequencing.
Nitrate and nitrite levels in saliva, blood and urine 
samples will be determined using ozone chemilumines-
cence as previously described.31 32 In brief, total nitrate 
and nitrite concentration (termed ‘NOx’) will be deter-
mined by adding samples to 0.1 mol/L vanadium (III) 
chloride in 1M hydrochloric acid refluxing at 95°C under 
nitrogen. Nitrite concentration will be determined by the 
addition of samples to 0.09 mol/L potassium iodide in 
glacial acetic acid under nitrogen at room temperature. 
Nitrate concentration will be calculated by the subtrac-
tion of (nitrite) from (NOx). All measurements will be 
conducted by an individual blinded to the intervention. 
In addition, a sample from each batch of juice sent to 
each volunteer will be analysed for NOx content.
Pulse wave analysis and pulse wave velocity
Pulse wave analysis (PWA) and PWV are the measures 
of arterial stiffness, which will be determined by a non- 
invasive Vicorder device (Skidmore Medical, Bristol, 
UK). For PWA, the pulse wave will be recorded from the 
brachial cuff applied to the non- dominant arm. For PWV, 
the pulse wave will be simultaneously recorded from the 
carotid and femoral site using an oscillometric method. 
A small, inflatable neck pad will be placed directly over 
a carotid artery and secured around the neck by a Velcro 
tab and a cuff will also be placed around the patient’s ipsi-
lateral upper thigh. Both carotid and femoral cuffs will 
be simultaneously inflated automatically to 65 mm Hg 
and the corresponding oscillometric signal from each 
cuff digitally analysed to extract the pulse time delay. 
To estimate the aortic length, the distance between the 
sternal notch and the thigh cuff will be measured. From 
these measurements, PWV can be derived as PWV=aortic 
distance/pulse time delay.33
Flow-mediated dilation
FMD will be used to non- invasively assess endothelial func-
tion, using vascular ultrasound to measure the increase in 
brachial artery diameter in response to increased flow34 
as previously described.35 A high- resolution external 
vascular ultrasound Siemens/Acuson Sequoia C256 
Colour Doppler with a 7.0 MHz linear- array transducer 
supported by a stereotactic clamp will be used to assess 
the vessel diameter in the right arm. The vessel will be 
scanned in longitudinal section and the centre will be 
identified when the clearest views of the anterior and 
posterior artery walls have been obtained. Images will 
be magnified with a resolution box function and images 
of the brachial artery acquired continuously using semi- 
automated edge detection software (FMD Studio, Quipu 
s.r.l, Pisa, Italy) and analysed in real time. An automatic 
mathematical contour tracking operator locates the 
pulsed- wave Doppler of the brachial artery, which will 
be used to measure the diameter and blood flow velocity 
continuously for 1 min at baseline, then during 5 min of 
reduced blood flow (induced by inflation to 300 mm Hg 
of a pneumatic cuff placed on the right forearm site distal 
to the segment of artery being analysed), and finally for 
a further 5 min during the reactive hyperaemia following 
cuff release. FMD is defined as the maximum percentage 
increase in vessel diameter during the reactive hyper-
aemia. This procedure will be performed at visit 1 (base-
line) and visit 3 (16 weeks). In some volunteers, following 
FMD, 0.4 mg of sublingual glyceryl trinitrate will be 
administered at visit 1 and visit 3 to determine whether 
changes in FMD responses following intervention might 
be due to changes in smooth muscle reactivity.
Transthoracic echocardiography
At visits 1 and 3, echocardiography is also performed to 
assess LV diastolic function. Images will be acquired for 
measures of LV diastolic function including left atrial 
end- diastolic volumes, pulmonary vein s/d ratio, mitral 
valve E/A ratio and E/e’.29 36 Images will be acquired and 
analysed by an operator accredited by the British Society 
of Echocardiography.
Cardiovascular MRI
The most accurate and reproducible measurements 
of LVH are made by CMR.37 At visits 1 and 3, CMR in 
the NITRATE- LVH arm and those that consent in the 
NITRATE- CBP arm will be used to assess LV mass, volumes 
and ejection fraction, T1 and T2 mapping, patterns of 
late gadolinium enhancement (LGE), aortic distensi-
bility and PWV. Participants will have a peripheral venous 
cannula inserted and gadolinium injected at doses up to 
0.2 mmol/kg.
To allow a thorough assessment of cardiac function, the 
following imaging sequences will be undertaken:
 ► Scout images, including black and white blood trans-
verse slices of the thorax.
 ► Long- axis cines (four- chamber, two- chamber, left 
ventricular outflow tract (LVOT-1 and LVOT-2), aortic 
valve short axis).
 ► Short- axis cine stack.
 ► T1 and T2 mapping.
6 Lau CWZ, et al. BMJ Open 2020;10:e034399. doi:10.1136/bmjopen-2019-034399
Open access 
 ► LGE in the four- chamber, two- chamber, three- 
chamber views and short- axis stack.
 ► Postcontrast T1 mapping for extracellular volume 
quantification.
 ► Sagittal aortic views and aortic flow sequences for 
assessment of aortic distensibility and PWV.
Short- axis images will be acquired using standard 
sequences, that is, 10–12 slices of 8 mm thickness with 
2 mm gap to achieve whole LV coverage. This is under-
taken with the patient in held expiration. Cine and LGE 
short- axis stacks will be acquired using identical scanning 
geometry to assure correct image registration.
The following offline parameters will be measured:
 ► Presence of significant extracardiac pathology.
 ► LV ejection fraction, volumes and mass.
 ► Distribution of LGE.
 ► Analysis of pre and post contrast T1 mapping and 
T2 mapping. Short- axis images will be segmented 
according to the American Heart Association (AHA) 
model as previously described.38
 ► Aortic distensibility and PWV.
For the analysis of study outcomes, each study will be 
anonymised by a third party. This will be separate from 
the study identification (ID) to avoid bias between 
pretreatment and post- treatment studies. Documentation 
of this anonymisation will be stored on a secure server 
at the Barts CVCTU, with unblinding for clinical reasons 
as necessary. The principal investigator (PI) will be 
informed if this is necessary. Study analysis will occur in 
batches to prevent bias. For the assessment of LV volumes 
and mass, two readers will undertake assessment of inter 
and intraobserver variation prior to analysis of blinded 
study images. Image analysis will be overseen and adjudi-
cated by an experienced level three CMR reader (JCM).
End of study definition
The study will end after the final visit at week 16.
stAtIstICAl AnAlysIs
In this study, we intend to recruit 80 patients in each 
treatment arm with stratification of 80 patients overall 
recruited to NITRATE- LVH and 80 recruited to the 
NITRATE- CBP arms (total n=160). This sample size will 
empower our trial to test for the primary and all major 
secondary endpoints listed below.
We determined the sample size using G*Power 3.0. 
Calculations were based on unpaired t- tests, a significance 
level of 0.05 (two tailed) and the relevant SD of the mean 
difference from published studies with reproducibility 
data: central systolic BP 1.7 mm Hg,39 LV mass 9.9 g,40 
CMR PWV 0.45 m/s,41 Vicorder PWV 0.29 m/s.41 For BP, 
we used measures of SD of systolic BP (as it has greater SD 
than diastolic BP) from the placebo limb of our previous 
intervention trial in hypertensive patients13: clinic systolic 
BP 8.4 mm Hg; ambulatory systolic BP 4.9 mm Hg; home 
systolic BP 3.9 mm Hg. International consensus docu-
ments on the optimal method for ultrasound FMD suggest 
using laboratory- specific data in sample size calculation 
and have suggested that 40 participants in a parallel study 
are sufficient to determine statistically important differ-
ences.35 In a study of 4- week dietary nitrate intervention 
in hypertensive patients, SD of repeated measures of FMD 
in the placebo group was 0.6, while the mean difference 
between the groups was 1.0%,13 an SD of 1.1.
Primary endpoints
For the individual stratified subgroups:
NITRATE-LVH
For the primary endpoint of LV mass regression, we have 
a power of 95% for detecting a 9 g LV mass change (~6% 
change for a mildly hypertrophied heart of 150 g). Previ-
ously published data showed a 10% reduction in LV mass 
in hypertensives after 3 months treatment with spirono-
lactone.42 Furthermore, dietary advice aimed at BP 
reduction in the Treatment of Mild Hypertension Study 
(TOMHS) demonstrated mean 9/9 mm Hg BP reduction 
and ~20 g LV mass reduction from baseline ~200 g (by 
echocardiography) at 3 months post intervention, repre-
senting ~10% reduction in LV mass.43
NITRATE-CBP
For non- CMR PWV, we have a power of >95% for 
detecting a 0.6 m/s absolute change (previously demon-
strated following 4 weeks dietary nitrate in hypertensive 
patients13). For CMR determined PWV, we have a power 
of >95% for detecting a 0.6 m/s absolute change.13 For 
our primary end point of reduction in central systolic BP, 
we expect a scaled reduction in BP relative to observed 
decreases in brachial BP (8.7 mm Hg clinic brachial 
systolic BP)13 though evidence suggests that low- dose 
intravenous nitrite infusions act to selectively lower 
central BP in preference to brachial BP and therefore 
expected differences may be larger.44 Nevertheless, using 
our conservative estimate based on two- thirds brachial BP 
effect, we have >90% power to detect a 5.8 mm Hg differ-
ence in central systolic BP.
In post hoc analyses, data will be combined from the 
two groups to assess the overall impact of inorganic nitrate 
versus placebo on the entire cohort for BP, nitrate and 
nitrite analysis. In addition, correlation analyses will be 
conducted using Pearson’s correlation between measures 
of NOx, LV mass, BP and PWV.
secondary endpoints
a. Ultrasound FMD (%), >90% power for detecting a 
1.0% absolute change from a reduced FMD of ~5%.13
b. Brachial BP
i. Clinic>85% power to detect 7 mm Hg absolute 
change.13
ii. Ambulatory >95% power to detect 7 mm Hg abso-
lute change.13
iii. Home >85% power to detect 7 mm Hg absolute 
change.13 The change observed in our 4 week study 
was ~7 mm Hg13 but with reduced measurement 
frequency, the possibility of increase measurement 
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variability, and therefore, SD was arbitrarily dou-
bled for this calculation.
Our sample size calculations assume a drop- out 
rate of 15% (non- compliance with dietary interven-
tion or follow- up visits) based on our centres previous 
observations.
Data will be analysed on an intention- to- treat basis. The 
data will be compared by multivariable regression anal-
ysis for each functional measure. The change from base-
line in prespecified primary, secondary and exploratory 
outcomes will be compared between groups by Student’s 
t- test. We will adjust the results for multiple variables: sex, 
age, weight, body mass index and the initial differences 
between groups in LV mass.
Written approval from the research ethics committee 
(REC) was obtained along with final sponsorship and 
NHS Health Research Authority approval.
safety considerations
The intervention is 70 mL of beetroot juice concentrate 
or nitrate- deplete beetroot juice (placebo; James White 
Drinks). The nitrate is extracted using the same anion 
exchange technique to remove inorganic nitrate from 
the general drinking water supplies. There are no known 
serious side effects from these interventions and nitrate- 
free juice is classified as a foodstuff. In addition, several 
recent publications using the placebo juice are now avail-
able.45–47 In the unlikely event of a serious adverse event 
(SAE) occurring directly as a result of the intervention, 
this would need to be reviewed by the chief investigator 
and the procedures followed as described below.
safety reporting
An AE will be documented in the participants’ medical 
notes and the case report form and followed up by the 
investigators. SAEs will be reported to the sponsor and 
REC where in the opinion of the chief investigator the 
event was either ‘related’ (ie, resulted from administra-
tion of research procedures) and ‘unexpected’ (ie, the 
type of event is not an expected occurrence).
SAEs considered to be ‘related’ and ‘unexpected’ 
will be recorded in the participants’ notes, the sponsor 
SAE form and reported to the sponsor’s joint research 
management office within 24 hours of the research team 
being notified, and to the main REC within 15 days. The 
coinvestigators will be authorised to sign SAE forms in the 
absence of the PI. The intervention for the participant 
will be unblinded in the reporting of an ‘unexpected and 
related’ SAE, performed by an individual independent of 
the study procedures and will allow the investigators to 
remain blinded. The unblinding of single cases will only 
be performed if necessary for the safety of a participant.
MonItorIng
trial steering Committee
The trial steering committee (TSC) is composed of three 
independent experts in the fields of: CMR, hypertension 
and clinical trials along with the investigators and the 
data monitor and two lay members. This committee met 
before participant recruitment and will meet annually to 
assess safety, feasibility or any other arising problems and 
their recommendations followed.
data safety and monitoring board
The trial is classified as low- risk and does not require 
the formal setting up of a data safety and monitoring 
board (DSMB), however, a DSMB has been established 
comprising a clinical trials physician, statistician and 
cardiovascular physician. The DSMB met to review data 
after 20 patients in each study arm had completed their 
involvement, to advise about planned sample size and 
safety signals. The study will be subject to monitoring by 
the sponsor, Queen Mary University of London, in accor-
dance with their policies. Any monitoring findings will be 
relayed to the TSC by the chief investigator and acted in 
the best interest of patients, sponsor and funder.
Ethics and dissemination
Data collection will be completed by the third quarter 
of 2020. Primary and secondary analysis will start imme-
diately after data collection is completed, with an aim 
to prepare publications for submission in 2021. The 
results of the trial will be published according to the 
Consolidated Standards of Reporting Trials statement. 
Dissemination of results will be in peer- reviewed journal 
publications and presentations at national and interna-
tional conferences.
summary
This is the first randomised- controlled trial assessing 
the use of prolonged dietary nitrate treatment in 
hypertension- induced target organ damage, specifically 
LVH and arterial stiffness. This study will determine 
the potential of prolonged dietary nitrate as adjunctive 
therapy in patients with sub optimally controlled hyper-
tension on antihypertensive medication.
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